| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Internal Medicine, Harbor-UCLA Medical Center, UCLA School of Medicine, Torrance, California
Address reprint requests to: John A. Tayek, M.D., 1000 W. Carson Street, Box 428, Torrance, CA 90509. E-mail: tayek{at}humc.edu
Objectives: Arginine is converted in the endothelial cells to nitric oxide (NO) and citrulline. NO is a potent vasodilator in humans, but diabetics may have a reduced generation of NO which results in endothelial dysfunction. The aim of this study was to evaluate the effects of oral arginine on nitric oxide production, counter-regulatory hormones and blood pressure in mildly hypertensive type 2 diabetic patients.
Methods: A prospective, crossover clinical trial was performed over a three-day stay in the General Clinical Research Center. Six patients with type 2 diabetes mellitus and mild hypertension consented and were given orally three grams of arginine per hour for 10 hours on either day 2 or day 3. On both days 2 and 3, blood pressure was monitored between 5 AM and 4 PM and mean pressure determined.
Results: Oral arginine increased plasma citrulline from 31.3 ± 6.0 to 41.5 ± 6.0 µmol/L (mean ± SEM; p < 0.05) which may reflect an increased conversion of arginine into NO and citrulline. Arginine reduced systolic BP from 135 ± 7 to 123 ± 8 mmHg; p < 0.05. Diastolic BP fell from 86.9 ± 1.7 to 80.7 ± 2.4 mmHg; p < 0.05). The reduction in BP was noted to occur two hours after starting oral arginine, and BP returned to normal within one hour of stopping the arginine. The oral arginine had no effect on C-peptide, insulin or other hormone concentrations.
Conclusions: These data suggest that oral arginine may increase endothelial nitric oxide synthase (NOS) to increase vascular NO and temporally reduce blood pressure in mildly hypertensive type 2 diabetic patients.
Key words: blood pressure, nitric oxide, arginine
This article has been cited by other articles:
|
|
 |
|
  M. J. Romero, D. H. Platt, H. E. Tawfik, M. Labazi, A. B. El-Remessy, M. Bartoli, R. B. Caldwell, and R. W. Caldwell Diabetes-induced Coronary Vascular Dysfunction Involves Increased Arginase Activity Circ. Res., January 4, 2008; 102(1): 95 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Vasilijevic, B. Buzadzic, A. Korac, V. Petrovic, A. Jankovic, and B. Korac Beneficial effects of L-arginine nitric oxide-producing pathway in rats treated with alloxan J. Physiol., November 1, 2007; 584(3): 921 - 933. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hu, M. Chouinard, A. L. Cox, P. Sipes, M. Marcelo, J. Ficorilli, S. Li, H. Gao, T. P. Ryan, M. D. Michael, et al. Farnesoid X Receptor Agonist Reduces Serum Asymmetric Dimethylarginine Levels through Hepatic Dimethylarginine Dimethylaminohydrolase-1 Gene Regulation J. Biol. Chem., December 29, 2006; 281(52): 39831 - 39838. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Fu, T. E. Haynes, R. Kohli, J. Hu, W. Shi, T. E. Spencer, R. J. Carroll, C. J. Meininger, and G. Wu Dietary L-Arginine Supplementation Reduces Fat Mass in Zucker Diabetic Fatty Rats J. Nutr., April 1, 2005; 135(4): 714 - 721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. E. James, D. Lang, T. Tufnell-Barret, A. B. Milsom, and M. P. Frenneaux Vasorelaxation by Red Blood Cells and Impairment in Diabetes: Reduced Nitric Oxide and Oxygen Delivery by Glycated Hemoglobin Circ. Res., April 16, 2004; 94(7): 976 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Kohli, C. J. Meininger, T. E. Haynes, W. Yan, J. T. Self, and G. Wu Dietary L-Arginine Supplementation Enhances Endothelial Nitric Oxide Synthesis in Streptozotocin-Induced Diabetic Rats J. Nutr., March 1, 2004; 134(3): 600 - 608. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
